Clinical trial
A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With PCV.
NCT02495181 is registered in ClinicalTrials.gov with Association for Innovation and Biomedical Research on Light and Image as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With PCV.
- Lead sponsor
- Association for Innovation and Biomedical Research on Light and Image
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 23, 2015
- Completion date
- December 17, 2019
- Enrollment
- 50 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.